The A20 protein interacts with the Epstein-Barr virus latent membrane protein 1 (LMP1) and alters the LMP1/TRAF1/TRADD complex

Virology

Volumn 264, Issue 1, 1999, Pages 159-166

  Fries, Katherine L ^a   Miller, William E ^a   Raab Traub, Nancy ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LATENT MEMBRANE PROTEIN 1; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS PROTEIN A20;

ARTICLE; BURKITT LYMPHOMA; CELL LINE; CONTROLLED STUDY; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; NASOPHARYNX CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION;

DNA VIRUSES; HUMAN HERPESVIRUS 4;

EID: 0033544375     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1999.9980     Document Type: Article

References (39)

1. Aster J., Robertson E., Hasserjian R., Turner J., Kieff E., Sklar J. Oncogenic forms of NOTCH1 lacking either the primary binding site for RBP-Jkappa or nuclear localization sequences retain the ability to associate with RBP-Jkappa and activate transcription. J. Biol. Chem. 272:1997;11336-11343.
2. Cheng G., Baltimore D. TANK, a co-inducer with TRAF2 of TNF-and CD40L-mediated NF-κB activation. Genes Dev. 10:1996;963-973.
3. Desgranges C., Wolf H., de The G., Shanmugaratnam K., Ellouz R., Cammoun N., Klein G., zur Hausen H. Nasopharyngeal carcinoma X. Presence of Epstein-Barr Virus genomes in epithelial cells of tumors from high and medium risk areas. Int. J. Cancer. 16:1975;7-15.
4. Devergne O., Hatzivassiliou E., Izumi K., Kaye K., Kleijnen M., Kieff E., Mosialos G. Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr Virus LMP1 domain important for B lymphocyte transformation: Role in NF-kB Activation. Mol. Cell. Biol. 16:1996;7098-7108.
5. Devergne O., McFarland E., Mosialos G., Izumi K., Ware C., Kieff E. Role of the TRAF binding Site and NF-kB activation in Epstein-Barr Virus latent membrane protein 1-induced cell gene expression. J. Virol. 72:1998;7900-7908.
6. Eliopoulos A., Blake S., Floettmann J., Rowe M., Young L. Epstein-Barr Virus-encoded latent membrane protein 1 activates the JNK pathway through its extreme C terminus via a mechanism involving TRADD and TRAF2. J. Virol. 73:1999;1023-1035.
7. Eliopoulus A. G., Stack M., Dawson C., Kaye K., Hodgkin L., Sihota S., Rowe M., Young L. Epstein-Barr virus-encoded LMP1 and CD40 mediate IL-6 production in epithelial cells via an NF-κB pathway involving TNF receptor -associated factors. Oncogene. 14:1997;2899-2916.
8. Fries K. L., Miller W. E., Raab-Traub N. Epstein-Barr virus latent membrane protein 1 blocks p53-mediated apoptosis through the induction of the A20 gene. J. Virol. 70:1996;8653-8659.
9. Fries K., Sculley T., Webster-Cyriaque J., Rajadurai P., Sadler R., Raab-Traub N. Identification of a novel protein encoded by the BamHIA region of the Epstein-Barr virus. J. Virol. 71:1997;2765-2771.
10. Gedrich R. W., Gilfillan M. C., Duckett C. S., Dongen J. L., Thompson C. B. CD30 contains two binding sites with different specificities for members of the tumor necrosis factor-receptor-associated factor family of signal transducing proteins. J. Biol. Chem. 271:1996;12852-12858.
11. Geser A., Lenoir G., Anvret M., Bornkamm G. W., Klein G., Williams E. H., Wright D. H., The G. d. Epstein-Barr virus markers in a series of Burkitt's lymphomas from the West Nile District, Uganda. Eur. J. Cancer Clin. Oncol. 19:1983;1394-1404.
12. Hanto D. W., Frizzera G. F., Gajl-Peczalska K. J., Sakamoto K., Purtilo D. T., Balfour H. H., Simmons R. L., Najarian J. S. Epstein-Barr virus-induced B-cell lymphoma after renal transplantation. N. Engl. J. Med. 306:1982;913-918.
13. Henderson S., Rowe M., Gregory C., Croom-Carter D., Wang F., Longnecker R., Kieff E., Rickinson A. Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell. 65:1991;1107-1115.
14. Hsu H., Shu H.-B., Pan M.-G., Goeddel D. V. TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell. 84:1996;299-308.
15. Hu H. M., O'Rourke K., Boguski M. S., Dixit V. M. A novel RING finger protein interacts with the cytoplasmic domain of CD40. J. Biol. Chem. 269:1994;30069-30072.
16. Huen D. S., Henderson S. A., Croom-Carter S., Rowe M. The Epstein-Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-kB and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain. Oncogene. 10:1995;549-560.
17. Izumi K. M., Kaye K. M., Kieff E. D. The Epstein-Barr virus LMP1 amino acid sequence that engages tumor necrosis factor receptor associated factors is critical for primary B lymphocyte growth transformation. Proc. Natl. Acad. Sci. USA. 94:1997;1447-1452.
18. Izumi K., Kieff E. The Epstein-Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptor-associated death domain protein to mediate B-lymphocyte growth transfromation and activate NF-κB. Proc. Natl. Acad. Sci. USA. 94:1997;12592-12597.
19. Jaattela M., Mouritzen H., Elling F., Bastholm L. A20 zinc finger protein inhibits TNF and IL-1 signaling. J. Immunol. 156:1996;1166-1173.
20. Katz B. Z., Raab-Traub N., Miller G. Latent and replicating forms of Epstein-Barr virus DNA in lymphomas and lymphoproliferative diseases. J. Infect. Dis. 160:1989;589-598.
21. Kaye K., Devergne O., Harada J., Izumi K., Yalamanchili R., Kieff E., Mosialos G. Tumor necrosis factor receptor associated factor 2 is a mediator of NF-kB activation by latent infection membrane protein 1, the Epstein-Barr virus transforming protein. Proc. Natl. Acad. Sci. USA. 93:1996;11085-11090.
22. Kaye K. M., Izumi K. M., Kieff E. Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc. Natl. Acad. Sci. USA. 90:1993;9150-9154.
23. Laherty C. D., Hu H. M., Opipari A. W., Wang F., Dixit V. M. The Epstein-Barr virus LMP1 gene product induces A20 zinc finger protein expression by activating NF-κB. J. Biol. Chem. 267:1992;24157-24160.
24. Miller, W, Cheshire, J, and, Raab-Traub, N. in press, The Epstein-Barr virus latent menbrane protein 1 induces EGFR expression through interaction with TRAF3, Mol. Cell. Biol. 18, in press.
25. Miller W. E., Earp H. S., Raab-Traub N. The Epstein-Barr Virus latent membrane protein 1 induces expression of the epidermal growth Factor receptor. J. Virol. 69:1995;4390-4398.
26. Miller W. E., Mosialos G., Kieff E., Raab-Traub N. Epstein-Barr Virus LMP1 induction of the EGFR is mediated through a TRAF signaling pathway distinct from NF-κB activation. J. Virol. 71:1997;586-594.
27. Mitchell T., Sugden B. Stimulation of NF-kB-mediated transcription by mutant derivatives of the latent membrane protein of Epstein-Barr Virus. J. Virol. 69:1995;2968-2976.
28. Mosialos G., Birkenbach M., Yalamanchili R., VanArsdale T., Ware C., Kieff E. The Epstein-Barr virus transforming protein LMP1 engages signalling proteins for the tumor necrosis factor receptor family. Cell. 80:1995;389-399.
29. Pathmanathan R., Prasaad U., Sadler R., Flynn K., Raab-Traub N. Clonal proliferation of cells infected with Epstein-Barr Virus in preinvasive lesions related to nasopharyngeal carcinoma. N. Engl. J. Med. 333:1995;693-698.
30. Peng M., Lundgren E. Transient expression of the Epstein-Barr virus LMP1 gene in B-cell chronic lymphocytic leukemia cells, T cells, and hematopoietic cell lines: Cell-type-independent-induction of CD23, CD21, and ICAM-1. Leukemia. 7:1993;104-112.
31. Raab-Traub N., Flynn K. The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation. Cell. 47:1986;883-889.
32. Raab-Traub N., Flynn K., Pearson G., Huang A., Levine P., Lanier A., Pagano J. The differentiated form of nasopharyngeal carcinoma contains Epstein-Barr virus DNA. Int. J. Cancer. 39:1987;25-29.
33. Rothe M., Sarma V., Dixit V. M., Goeddel D. V. TRAF-2 mediated activation of NF-kB by TNF receptor 2 and CD40. Science. 269:1995;1424-1427.
34. Song H., Rothe M., Goeddel D. The tumor necrosis factor-inducible zinc finger protein A20 interacts with TRAF1/TRAF2 and inhibits NF-kB activation. Proc. Natl. Acad. Sci. USA. 93:1996;6721-6725.
35. Wang D., Liebowitz D., Kieff E. An Epstein-Barr virus membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell. 43:1985;831-840.
36. Wang D., Liebowitz D., Kieff E. The truncated form of the Epstein-Barr virus latent-infection membrane protein expressed in virus replication does not transform rodent fibroblasts. J. Virol. 62:1988a;2337-2346.
37. Wang D., Liebowitz D., Wang F., Gregory C., Rickinson A., Larson R., Springer T., Kieff E. Epstein-Barr virus latent infection membrane protein alters the human B-lymphocyte phenotype: deletion of the amino terminus abolishes activity. J. Virol. 62:1988b;4173-4184.
38. Wang F., Gregory C., Sample C., Rowe M., Liebowitz D., Murray R., Rickinson A., Kieff E. Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. J. Virol. 64:1990;2309-2318.
39. zurHausen H., Schulte-Holthausen H., Klein G., Henley W., Henley G., Clifford P., Santesson L. EBV DNA in biopsies of Burkitt tumors and anaplastic carcinomas of the nasopharynx. Nature. 228:1970;1056-1058.